Uwe P.
- Country
- Germany
- Department
- Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Phase II Study of Imetelstat Sodium in High‑Risk MDS and AML Patients Refractory to Hypomethylating Agent Therapy
- Efficacy and Safety of Galinpepimut-S Versus Best Available Therapy in Acute Myeloid Leukemia Patients in Second or Later Complete Remission
Data & Insights
Has run more than one trial at 31 of 119 partner sites.
Specializations
Acute Myeloid Leukemia Research
The investigator specializes in treating various forms of acute myeloid leukemia (AML), with particular emphasis on relapsed and refractory AML cases.
- CD123-positive AML interventions
- High-risk AML management
- Novel therapeutic combinations
Expertise extends to innovative treatments including immunotherapy approaches and targeted molecular therapies.
Myelodysplastic Syndrome Studies
Focused on advancing treatment options for myelodysplastic syndrome (MDS), particularly in cases with specific genetic mutations like IDH2.
- High-risk MDS interventions
- Treatment-resistant MDS
- Novel therapeutic approaches
Specializes in developing strategies for both low and high-risk MDS patients.
Advanced Therapeutic Applications
Investigates cutting-edge treatments including targeted molecular therapies and combination therapeutic approaches.
- Novel drug development
- Hypomethylating agent therapies
- Innovative treatment combinations
Works with emerging therapeutic agents and established treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.